CD19 and neoplasm: The same research team subsequently employed a new MPC inhibitor, MITO-66, which effectively triggered a stem cell-like memory phenotype and improved anti-tumor effectiveness of CD19 CAR T cells from healthy donors and r/r B cell malignancy patients, facilitating clinical application (255).